COMMISSION DECISION

of 24.11.2023

appointing a member and an alternate member of the Pharmacovigilance Risk Assessment Committee to represent patient organisations
COMMISSION DECISION

of 24.11.2023

appointing a member and an alternate member of the Pharmacovigilance Risk Assessment Committee to represent patient organisations

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency¹, and in particular Article 61a(1), point (d), thereof,

Whereas:

(1) Article 61a(1) of Regulation (EC) No 726/2004 requires that the Commission appoints representatives of healthcare professionals and patient organisations to the European Medicines Agency Pharmacovigilance Risk Assessment Committee.

(2) In accordance with Article 61a(1) of Regulation (EC) No 726/2004, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation including the reserve list, for the applications, received in the framework of this call for expression of interest.

(3) By its decision of 2 May 2022², the Commission appointed members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patient associations for a term of three years starting on 1 May 2022 and set up a reserve list by order of merit.

(4) Where a member or alternate representing healthcare professionals appointed by this decision is no longer capable of contributing efficiently to the work of the Committee, or resigns, the Commission may replace this member from the reserve list, for the remaining duration of the member’s mandate.

(5) Mr Declan Noone resigned from his office with an effective date of 3 July 2023 and has to be replaced until the end of his term of office. It is his alternate Mr Marko Korenjak who replaces Mr Noone. As alternate, Mr Marko Korenjak confirmed his interest and availability to become member.

(6) As alternate Mr Marko Korenjak has to be replaced by a candidate from the reserve list. Mr Michał Rataj from the reserve list confirmed his interest and availability to replace the current alternate.

² C(2022) 2729 final, COMMISSION DECISION of 2.5.2022 appointing members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patients’ organisations.
HAS DECIDED AS FOLLOWS:

Article 1
Mr Marko Korenjak is hereby appointed as member of the Pharmacovigilance Risk Assessment Committee to represent patient organisations until 1 May 2025.

Article 2
Mr Michał Rataj is hereby appointed as alternate member of the Pharmacovigilance Risk Assessment Committee to represent patient organisations until 1 May 2025.

Done at Brussels, 24.11.2023

For the Commission,
Stella KYRIAKIDES
Member of the Commission